Skip to content

Bcr-Abl Fusion Gene Detection by Qualitative PCR (Blood)

Published: August 9, 2026Updated: August 16, 2026

This test checks for the presence of a genetic change called the BCR-ABL fusion gene, which can occur in certain blood cancers like chronic myeloid leukemia (CML).

Quick summary

["This test helps monitor treatment response and disease status in blood cancer patients."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
51867-0
Short code
t(9;22)(ABL1,BCR) Bld/T FISH
Synonyms
t(9;22)(ABL1,BCR) Bld/T FISH
Category
coagulation
Sample
whole-blood
Container
Lavender-top (EDTA)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
fish
Specimen volume
3 mL
Stability
Room temperature: 4h, Refrigerated: 24h
Hemolysis max
0
Lipemia max
0
Icterus max
0
TAT
4–24 hours
Order
routine

Why This Test Is Done

Your doctor may order this test if you have a blood cancer like chronic myeloid leukemia (CML) or if you’re undergoing treatment for such a condition. It helps track whether the cancer is responding to treatment or if it’s spreading.

How the Test Works

Blood is collected and analyzed to detect the BCR-ABL fusion gene using a special type of lab test called qualitative PCR (Polymerase Chain Reaction). This test looks for a specific genetic sequence that is only present in certain blood cancers.

What to Expect Before the Test

No special preparation is needed for this test. You’ll have a small needle inserted into your arm to draw blood, similar to other blood tests. The process usually takes a few minutes.

What to Expect After the Test

After the blood is drawn, you may feel a small bruise or soreness at the site, which typically goes away quickly. You can resume your normal activities right after the test.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

The BCR-ABL test is crucial for diagnosing and managing chronic myeloid leukemia (CML). Detecting the fusion gene confirms the diagnosis and helps determine the appropriate treatment plan. Regular testing during treatment allows doctors to monitor the disease’s progression and adjust therapy as needed to improve outcomes.

Short name

BCR-ABL Test

Frequently asked questions

What does a positive result mean?
A positive result means the BCR-ABL fusion gene is present in your blood, indicating the presence of chronic myeloid leukemia (CML) or a related blood cancer. This finding helps guide treatment decisions and ongoing monitoring.
What does a negative result mean?
A negative result means the BCR-ABL fusion gene is not detected in your blood sample at this time. This could mean the cancer is not present or is in a very early stage, but it does not rule out the possibility of CML entirely. Follow-up testing may be needed.
How often should I get this test?
Your doctor will determine the frequency of testing based on your treatment plan, disease stage, and response to therapy. Regular monitoring is essential to track the effectiveness of your treatment and ensure the best possible outcome.
  1. 1
    MedlinePlus — Laboratory TestsSource
  2. 2
    Lab Tests OnlineSource
  3. 3
    Mayo Clinic — Tests & ProceduresSource

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy